[{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PTX-252","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Pharmaceuticals \/ Pleco Therapeutics"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Plecoid","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Pharmaceuticals \/ Pleco Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).

                          Product Name : PTX-252

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 16, 2024

                          Lead Product(s) : PTX-252

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Pleco Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The Plecoid FDC product is a patented, innovative, clinical-stage candidate drug that combines chelating agents with different characteristics. Previous studies demonstrate that elevated levels of toxic metals are associated with inferior survival in pat...

                          Product Name : Plecoid

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 11, 2021

                          Lead Product(s) : Plecoid

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Pleco Therapeutics

                          Deal Size : $9.8 million

                          Deal Type : Partnership

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Clinical and preclinical data have demonstrated clinical safety of TriMix, together with its ability to amplify immune responses in multiple disease indications. Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 16, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Vub

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services will evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 30, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : TRIO Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank